Filtered By:
Specialty: Dermatology
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 964 results found since Jan 2013.
Safety and Efficacy of TGF- β1/COX-2 Silencing Therapeutic in Adults With Cutaneous Squamous Cell Carcinoma In Situ
J Drugs Dermatol. 2022 May 1;21(5):472-477. doi: 10.36849/JDD.6384.ABSTRACTThis single-center, open label, dose escalation cohort study evaluated the safety and efficacy of various doses of intralesional injections of TGF-β1/COX-2 combined with histidine-lysine polypeptide (siRNA/HKP) nanoparticle silencing therapeutic in patients with cutaneous in situ squamous cell carcinoma. Twenty-five patients (mean age: 67, SD: 10 years; 52% men) with cutaneous in situ squamous cell carcinoma participated. TGF-β1/COX-2 siRNA/HKP nanoparticle therapeutic was injected weekly for up to 6 weeks based on the following do...
Source: Journal of Drugs in Dermatology - May 9, 2022 Category: Dermatology Authors: Mark Nestor Brian Berman Patrick Lu Michael Molyneaux Source Type: research
